CN101305982B - 局部凝胶给药体系 - Google Patents
局部凝胶给药体系 Download PDFInfo
- Publication number
- CN101305982B CN101305982B CN2008100852167A CN200810085216A CN101305982B CN 101305982 B CN101305982 B CN 101305982B CN 2008100852167 A CN2008100852167 A CN 2008100852167A CN 200810085216 A CN200810085216 A CN 200810085216A CN 101305982 B CN101305982 B CN 101305982B
- Authority
- CN
- China
- Prior art keywords
- gel combination
- gel
- water
- clindamycin phosphate
- retinoic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229940042129 topical gel Drugs 0.000 title claims description 5
- 239000000203 mixture Substances 0.000 claims abstract description 138
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 66
- 206010000496 acne Diseases 0.000 claims abstract description 35
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 29
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 26
- 150000001875 compounds Chemical class 0.000 claims abstract description 26
- 208000017520 skin disease Diseases 0.000 claims abstract description 21
- 239000002904 solvent Substances 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 16
- 239000004094 surface-active agent Substances 0.000 claims abstract description 15
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 11
- 201000004700 rosacea Diseases 0.000 claims abstract description 8
- UFUVLHLTWXBHGZ-MGZQPHGTSA-N [(2r,3r,4s,5r,6r)-6-[(1s,2s)-2-chloro-1-[[(2s,4r)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] dihydrogen phosphate Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@@H](SC)O1 UFUVLHLTWXBHGZ-MGZQPHGTSA-N 0.000 claims description 84
- 238000002360 preparation method Methods 0.000 claims description 48
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 44
- 229930002330 retinoic acid Natural products 0.000 claims description 43
- 229960001727 tretinoin Drugs 0.000 claims description 43
- 229960002291 clindamycin phosphate Drugs 0.000 claims description 41
- 238000011282 treatment Methods 0.000 claims description 39
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 36
- 229920000642 polymer Polymers 0.000 claims description 28
- 230000002421 anti-septic effect Effects 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 22
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 17
- 206010048768 Dermatosis Diseases 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 15
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 15
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 15
- 229960002216 methylparaben Drugs 0.000 claims description 15
- 239000003513 alkali Substances 0.000 claims description 14
- 230000000699 topical effect Effects 0.000 claims description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 10
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 10
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 10
- 229940075510 carbopol 981 Drugs 0.000 claims description 9
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 9
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical group OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 9
- 229960000281 trometamol Drugs 0.000 claims description 9
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 8
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 229960003662 desonide Drugs 0.000 claims description 6
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 6
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 6
- 229960000282 metronidazole Drugs 0.000 claims description 6
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 6
- 229940068968 polysorbate 80 Drugs 0.000 claims description 6
- 229920000053 polysorbate 80 Polymers 0.000 claims description 6
- 229950008396 ulobetasol propionate Drugs 0.000 claims description 6
- BDSYKGHYMJNPAB-LICBFIPMSA-N ulobetasol propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]2(C)C[C@@H]1O BDSYKGHYMJNPAB-LICBFIPMSA-N 0.000 claims description 6
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 5
- 239000000473 propyl gallate Substances 0.000 claims description 5
- 229940075579 propyl gallate Drugs 0.000 claims description 5
- 235000010388 propyl gallate Nutrition 0.000 claims description 5
- -1 ester sodium salt Chemical class 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 4
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 3
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 3
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 3
- 229960002009 naproxen Drugs 0.000 claims description 3
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 3
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- 229920001219 Polysorbate 40 Polymers 0.000 claims description 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 2
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 2
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 claims description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 claims description 2
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 2
- 229940068977 polysorbate 20 Drugs 0.000 claims description 2
- 229940101027 polysorbate 40 Drugs 0.000 claims description 2
- 229940113124 polysorbate 60 Drugs 0.000 claims description 2
- 235000010199 sorbic acid Nutrition 0.000 claims description 2
- 239000004334 sorbic acid Substances 0.000 claims description 2
- 229940075582 sorbic acid Drugs 0.000 claims description 2
- 229950006451 sorbitan laurate Drugs 0.000 claims description 2
- 235000011067 sorbitan monolaureate Nutrition 0.000 claims description 2
- 239000001587 sorbitan monostearate Substances 0.000 claims description 2
- 235000011076 sorbitan monostearate Nutrition 0.000 claims description 2
- 229940035048 sorbitan monostearate Drugs 0.000 claims description 2
- 229950004959 sorbitan oleate Drugs 0.000 claims description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 2
- 229940033663 thimerosal Drugs 0.000 claims description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 229960004106 citric acid Drugs 0.000 claims 1
- 229940031726 laureth-10 Drugs 0.000 claims 1
- 229940045136 urea Drugs 0.000 claims 1
- 241001303601 Rosacea Species 0.000 abstract description 5
- 239000003755 preservative agent Substances 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 230000002335 preservative effect Effects 0.000 abstract description 3
- 239000000499 gel Substances 0.000 description 62
- 229940055343 clindagel Drugs 0.000 description 21
- 239000004480 active ingredient Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 18
- 238000003756 stirring Methods 0.000 description 18
- 210000003491 skin Anatomy 0.000 description 17
- 238000012360 testing method Methods 0.000 description 15
- 229940119716 cleocin-t Drugs 0.000 description 14
- 238000002156 mixing Methods 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000011248 coating agent Substances 0.000 description 11
- 238000000576 coating method Methods 0.000 description 11
- 239000006185 dispersion Substances 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 230000003115 biocidal effect Effects 0.000 description 9
- 230000003203 everyday effect Effects 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 239000006210 lotion Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 239000003246 corticosteroid Substances 0.000 description 8
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 8
- 206010012438 Dermatitis atopic Diseases 0.000 description 7
- 201000008937 atopic dermatitis Diseases 0.000 description 7
- 229960002227 clindamycin Drugs 0.000 description 7
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 239000011347 resin Substances 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 6
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 150000004492 retinoid derivatives Chemical class 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 206010037888 Rash pustular Diseases 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 208000029561 pustule Diseases 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000006184 cosolvent Substances 0.000 description 4
- 230000001815 facial effect Effects 0.000 description 4
- 239000010419 fine particle Substances 0.000 description 4
- 239000003349 gelling agent Substances 0.000 description 4
- 229960000890 hydrocortisone Drugs 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 4
- 238000010792 warming Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 3
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940063193 cleocin Drugs 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 238000005304 joining Methods 0.000 description 3
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 3
- 229960005287 lincomycin Drugs 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 2
- 206010000513 Acne pustular Diseases 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical group C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 229960002916 adapalene Drugs 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 229960004217 benzyl alcohol Drugs 0.000 description 2
- 229960004436 budesonide Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- BMCQMVFGOVHVNG-TUFAYURCSA-N cortisol 17-butyrate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O BMCQMVFGOVHVNG-TUFAYURCSA-N 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 229940031578 diisopropyl adipate Drugs 0.000 description 2
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 2
- 229960000878 docusate sodium Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229960001347 fluocinolone acetonide Drugs 0.000 description 2
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 2
- 229960000289 fluticasone propionate Drugs 0.000 description 2
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000009477 glass transition Effects 0.000 description 2
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical class COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 2
- 239000007970 homogeneous dispersion Substances 0.000 description 2
- 229960001524 hydrocortisone butyrate Drugs 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 150000002460 imidazoles Chemical class 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229940127554 medical product Drugs 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 229960002117 triamcinolone acetonide Drugs 0.000 description 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 2
- 229940005605 valeric acid Drugs 0.000 description 2
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 241000193880 Demodex folliculorum Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 241000047703 Nonion Species 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010064899 Vulvovaginal mycotic infection Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 229960001102 betamethasone dipropionate Drugs 0.000 description 1
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 description 1
- 229960004311 betamethasone valerate Drugs 0.000 description 1
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 229940082484 carbomer-934 Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000007765 cera alba Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 229960004703 clobetasol propionate Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical compound NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 description 1
- 229960002124 diflorasone diacetate Drugs 0.000 description 1
- BOBLHFUVNSFZPJ-JOYXJVLSSA-N diflorasone diacetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)COC(C)=O)(OC(C)=O)[C@@]2(C)C[C@@H]1O BOBLHFUVNSFZPJ-JOYXJVLSSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 150000004693 imidazolium salts Chemical class 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 229940113174 imidurea Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- XEBWQGVWTUSTLN-UHFFFAOYSA-M phenylmercury acetate Chemical compound CC(=O)O[Hg]C1=CC=CC=C1 XEBWQGVWTUSTLN-UHFFFAOYSA-M 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 208000030683 polygenic disease Diseases 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000013097 stability assessment Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 229940072172 tetracycline antibiotic Drugs 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 229940035658 visco-gel Drugs 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (40)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/632,508 | 2000-08-03 | ||
US09/632,508 US6387383B1 (en) | 2000-08-03 | 2000-08-03 | Topical low-viscosity gel composition |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN018150659A Division CN1460013B (zh) | 2000-08-03 | 2001-07-24 | 局部凝胶给药体系 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101305982A CN101305982A (zh) | 2008-11-19 |
CN101305982B true CN101305982B (zh) | 2011-12-14 |
Family
ID=24535786
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN018150659A Expired - Lifetime CN1460013B (zh) | 2000-08-03 | 2001-07-24 | 局部凝胶给药体系 |
CN2008100852167A Expired - Lifetime CN101305982B (zh) | 2000-08-03 | 2001-07-24 | 局部凝胶给药体系 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN018150659A Expired - Lifetime CN1460013B (zh) | 2000-08-03 | 2001-07-24 | 局部凝胶给药体系 |
Country Status (25)
Country | Link |
---|---|
US (2) | US6387383B1 (zh) |
EP (2) | EP1304992B1 (zh) |
JP (1) | JP4988129B2 (zh) |
KR (2) | KR20080036246A (zh) |
CN (2) | CN1460013B (zh) |
AR (1) | AR030093A1 (zh) |
AT (1) | ATE429922T1 (zh) |
AU (2) | AU7900201A (zh) |
BE (1) | BE2013C060I2 (zh) |
BR (1) | BR0113247A (zh) |
CA (1) | CA2417646C (zh) |
CY (3) | CY1109189T1 (zh) |
DE (1) | DE60138549D1 (zh) |
DK (2) | DK1304992T3 (zh) |
ES (2) | ES2437321T3 (zh) |
FR (1) | FR14C0053I1 (zh) |
HK (1) | HK1125847A1 (zh) |
LU (1) | LU92401I2 (zh) |
MX (1) | MXPA03001006A (zh) |
PL (1) | PL213237B1 (zh) |
PT (2) | PT2052714E (zh) |
RU (1) | RU2251410C2 (zh) |
SI (2) | SI2052714T1 (zh) |
WO (1) | WO2002011683A1 (zh) |
ZA (1) | ZA200301037B (zh) |
Families Citing this family (148)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020048596A1 (en) * | 1994-12-30 | 2002-04-25 | Gregor Cevc | Preparation for the transport of an active substance across barriers |
AUPN814496A0 (en) * | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
DE69825495T2 (de) | 1998-12-23 | 2005-07-28 | Idea Ag | Verbesserte formulierung zur topischen, nichtinvasiven anwendung in vivo |
ATE216875T1 (de) | 1999-01-27 | 2002-05-15 | Idea Ag | Nichtinvasive impfung durch die haut |
ATE216223T1 (de) | 1999-01-27 | 2002-05-15 | Idea Ag | Transnasaler transport bzw. impfung mit hochadaptierbaren trägern |
WO2001001962A1 (en) * | 1999-07-05 | 2001-01-11 | Idea Ag. | A method for the improvement of transport across adaptable semi-permeable barriers |
US6387383B1 (en) * | 2000-08-03 | 2002-05-14 | Dow Pharmaceutical Sciences | Topical low-viscosity gel composition |
US20060189552A1 (en) * | 2000-12-12 | 2006-08-24 | Mohan Vishnupad | Dispenser for dispensing three or more actives |
US7060732B2 (en) * | 2000-12-12 | 2006-06-13 | Imaginative Research Associates, Inc. | Antibiotic/benzoyl peroxide dispenser |
IL142037A0 (en) * | 2001-03-15 | 2002-03-10 | Agis Ind 1983 Ltd | Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug |
EP1385496A4 (en) | 2001-05-09 | 2006-03-29 | Univ Michigan | USE OF COMPOSITIONS FOR THE TREATMENT OF ROSACEA |
US7368122B1 (en) * | 2002-03-08 | 2008-05-06 | Dow Pharmaceutical Sciences | Skin cream |
US20050186141A1 (en) * | 2002-06-25 | 2005-08-25 | Acrux Dds Pty Ltd. | Transdermal aerosol compositions |
NZ537360A (en) * | 2002-06-25 | 2006-09-29 | Acrux Dds Pty Ltd | Transdermal delivery rate control using amorphous pharmaceutical compositions |
US20050181032A1 (en) * | 2002-06-25 | 2005-08-18 | Acrux Dds Pty Ltd. | Metastable pharmaceutical compositions |
US20040171561A1 (en) * | 2002-09-03 | 2004-09-02 | Popp Karl F. | Topical formulations for treatment of rosacea |
US20040167223A1 (en) * | 2002-09-03 | 2004-08-26 | Popp Karl F. | Topical antibacterial formulations |
US6906014B2 (en) * | 2002-09-10 | 2005-06-14 | Permatex, Inc. | Stabilized topical composition |
US7473432B2 (en) * | 2002-10-11 | 2009-01-06 | Idea Ag | NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery |
US7208485B2 (en) * | 2003-01-13 | 2007-04-24 | Chemagis Ltd. | Crystalline forms of halobetasol propionate |
ES2637956T3 (es) | 2003-01-24 | 2017-10-18 | Stiefel Research Australia Pty Ltd | Espuma farmacéutica |
EP1602372B1 (en) * | 2003-02-07 | 2016-08-31 | Mochida Pharmaceutical Co., Ltd. | Drug for improving prognosis for subarachnoid hemorrhage |
US20040202726A1 (en) * | 2003-04-10 | 2004-10-14 | Deshay Samuel L. | Topical blood pressure composition |
US8410102B2 (en) | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
US7439241B2 (en) | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
AU2004266658A1 (en) | 2003-08-12 | 2005-03-03 | 3M Innovative Properties Company | Hydroxylamine substituted imidazo-containing compounds |
AU2003265624B2 (en) * | 2003-08-21 | 2011-03-31 | Abeona Therapeutics Inc. | Liquid formulations for the prevention and treatment of mucosal diseases and disorders |
KR101106812B1 (ko) | 2003-08-27 | 2012-01-19 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 아릴옥시 및 아릴알킬렌옥시 치환된 이미다조퀴놀린 |
EP1660026A4 (en) | 2003-09-05 | 2008-07-16 | 3M Innovative Properties Co | TREATMENT FOR CD5 + B CELL LYMPHOMA |
US20060140990A1 (en) * | 2003-09-19 | 2006-06-29 | Drugtech Corporation | Composition for topical treatment of mixed vaginal infections |
BRPI0414500A (pt) * | 2003-09-19 | 2006-11-07 | Drugtech Corp | formulação farmacêutica composição para tratar uma infecção vaginal, e, métodos para tratar uma infecção vaginal, para estabilizar uma formulação de clindamicina, para tratar ou prevenir uma recorrência de uma infecção vaginal em uma paciente e para tratar condições vaginais |
ATE378360T1 (de) * | 2003-09-23 | 2007-11-15 | Akciju Sabiedriba Solainfarms | Polymere 3,5-dimethyl-1-adamantylammoniumsalze und deren verwendung in form von virustatika |
US7544697B2 (en) | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
JP5043435B2 (ja) | 2003-10-03 | 2012-10-10 | スリーエム イノベイティブ プロパティズ カンパニー | アルコキシ置換イミダゾキノリン |
US20050095215A1 (en) * | 2003-11-03 | 2005-05-05 | Popp Karl F. | Antimicrobial shampoo compositions |
EP1685129A4 (en) | 2003-11-14 | 2008-10-22 | 3M Innovative Properties Co | OXIMSUBSTITUTED IMIDAZORING CONNECTIONS |
JP2007511535A (ja) * | 2003-11-14 | 2007-05-10 | スリーエム イノベイティブ プロパティズ カンパニー | ヒドロキシルアミン置換イミダゾ環化合物 |
WO2005051317A2 (en) | 2003-11-25 | 2005-06-09 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
US8802853B2 (en) | 2003-12-29 | 2014-08-12 | 3M Innovative Properties Company | Arylalkenyl and arylalkynyl substituted imidazoquinolines |
WO2005065383A2 (en) * | 2003-12-30 | 2005-07-21 | Oculus Innovative Sciences, Inc. | Oxidative reductive potential water solution, processes for producing same and methods of using the same |
JP2007517044A (ja) | 2003-12-30 | 2007-06-28 | スリーエム イノベイティブ プロパティズ カンパニー | イミダゾキノリニル、イミダゾピリジニル、およびイミダゾナフチリジニルスルホンアミド |
US20050139808A1 (en) * | 2003-12-30 | 2005-06-30 | Oculus Innovative Sciences, Inc. | Oxidative reductive potential water solution and process for producing same |
US20050147570A1 (en) * | 2004-01-06 | 2005-07-07 | Nordsiek Michael T. | Methods of administering diclofenac compositions for treating photodamaged skin, rosacea and/or acne |
WO2005094531A2 (en) | 2004-03-24 | 2005-10-13 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
US7662855B2 (en) * | 2004-05-11 | 2010-02-16 | Imaginative Research Associates, Inc. | Retinoid solutions and formulations made therefrom |
US20060014834A1 (en) * | 2004-05-11 | 2006-01-19 | Mohan Vishnupad | Retinoid solutions and formulations made therefrom |
US20050255131A1 (en) * | 2004-05-11 | 2005-11-17 | Mohan Vishnupad | Clindamycin compositions and delivery system therefor |
NZ552325A (en) | 2004-05-25 | 2010-11-26 | Sansrosa Pharmaceutical Dev Inc | The use of alpha 2 andrenoceptor agonists such as brimonidine for treating inflammatory skin disorders |
US8741333B2 (en) * | 2004-06-07 | 2014-06-03 | Nuvo Research Inc. | Compositions and methods for treating dermatitis or psoriasis |
US8741332B2 (en) * | 2004-06-07 | 2014-06-03 | Nuvo Research Inc. | Compositions and methods for dermally treating neuropathic pain |
US8907153B2 (en) * | 2004-06-07 | 2014-12-09 | Nuvo Research Inc. | Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same |
US20070196452A1 (en) * | 2004-06-07 | 2007-08-23 | Jie Zhang | Flux-enabling compositions and methods for dermal delivery of drugs |
US8017779B2 (en) | 2004-06-15 | 2011-09-13 | 3M Innovative Properties Company | Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
FR2887149B1 (fr) * | 2005-06-17 | 2007-08-03 | Galderma Sa | Procede de solubilisation du metronidazole |
US7897609B2 (en) | 2004-06-18 | 2011-03-01 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
US8026366B2 (en) | 2004-06-18 | 2011-09-27 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
US20070259881A1 (en) * | 2004-06-18 | 2007-11-08 | Dellaria Joseph F Jr | Substituted Imidazo Ring Systems and Methods |
WO2006065280A2 (en) | 2004-06-18 | 2006-06-22 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods |
ITMI20041376A1 (it) * | 2004-07-09 | 2004-10-09 | Uni Campus Bio Medico Di Roma | Metodo di preparazione di un sistema polimerico biocompatibile per il rilascio farmacologico in uso topico e impieghi di detto sistema |
US20060093675A1 (en) * | 2004-10-29 | 2006-05-04 | Mathew Ebmeier | Intravaginal treatment of vaginal infections with metronidazole compositions |
JP2008519764A (ja) * | 2004-11-09 | 2008-06-12 | イマジナティブ リサーチ アソシエィツ インコーポレーテッド | レチノイド溶液及びそれからつくった調合物 |
KR20070086045A (ko) * | 2004-11-12 | 2007-08-27 | 이데아 아게 | 피부 상태 치료에서의 확대된 표면 집합체 |
US7943609B2 (en) | 2004-12-30 | 2011-05-17 | 3M Innovative Proprerties Company | Chiral fused [1,2]imidazo[4,5-C] ring compounds |
WO2006083440A2 (en) | 2004-12-30 | 2006-08-10 | 3M Innovative Properties Company | Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds |
CA2597092A1 (en) | 2005-02-04 | 2006-08-10 | Coley Pharmaceutical Group, Inc. | Aqueous gel formulations containing immune reponse modifiers |
EP1846405A2 (en) | 2005-02-11 | 2007-10-24 | 3M Innovative Properties Company | Oxime and hydroxylamine substituted imidazo 4,5-c ring compounds and methods |
JP2008535832A (ja) | 2005-04-01 | 2008-09-04 | コーリー ファーマシューティカル グループ,インコーポレイテッド | ピラゾロピリジン−1,4−ジアミン、およびそのアナログ |
CA2602590A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
WO2006121429A1 (en) * | 2005-05-06 | 2006-11-16 | Imaginative Research Associates, Inc. | Clindamycin compositions and delivery system therefor |
AU2006244260A1 (en) * | 2005-05-09 | 2006-11-16 | Drugtech Corporation | Modified-release pharmaceutical compositions |
NZ563946A (en) * | 2005-06-03 | 2012-02-24 | Acrux Dds Pty Ltd | Testosterone containing non-occlusive transdermal drug delivery composition for application to the arm pit / axilla |
AR054805A1 (es) * | 2005-06-29 | 2007-07-18 | Stiefel Laboratories | Composiciones topicas para el tratamiento de la piel |
KR20080055797A (ko) * | 2005-08-23 | 2008-06-19 | 닛산 가가쿠 고교 가부시키 가이샤 | 서방성 제제 |
US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
US8679545B2 (en) * | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
CA2635994A1 (en) * | 2006-01-05 | 2007-07-12 | Drugtech Corporation | Drug delivery system for bioadhesion to a vulvovaginal surface |
EA200870153A1 (ru) * | 2006-01-05 | 2008-12-30 | Драгтек Корпорейшн | Композиция и способ ее использования |
WO2007092312A2 (en) * | 2006-02-03 | 2007-08-16 | Stiefel Laboratories, Inc. | Topical skin treating compositions |
US20090053290A1 (en) * | 2006-03-08 | 2009-02-26 | Sand Bruce J | Transdermal drug delivery compositions and topical compositions for application on the skin |
KR101368107B1 (ko) | 2006-03-31 | 2014-03-14 | 스티펠 리서치 오스트레일리아 피티와이 리미티드 | 발포성 현탁겔 |
US20070280972A1 (en) * | 2006-04-25 | 2007-12-06 | Zars, Inc. | Adhesive solid gel-forming formulations for dermal drug delivery |
US7906506B2 (en) | 2006-07-12 | 2011-03-15 | 3M Innovative Properties Company | Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods |
CN101588791A (zh) | 2006-10-17 | 2009-11-25 | 纽沃研究公司 | 双氯芬酸凝胶 |
WO2008094910A2 (en) | 2007-01-30 | 2008-08-07 | Cypress Pharmaceutical, Inc. | Hyaluronate compositions |
US20080287373A1 (en) * | 2007-05-17 | 2008-11-20 | Popp Karl F | Topical skin treating kits |
US20080312245A1 (en) * | 2007-06-12 | 2008-12-18 | Longyan Xiao | Methods and compositions for treating acne and other infectious diseases |
JP2010539245A (ja) | 2007-09-14 | 2010-12-16 | 日東電工株式会社 | 薬物担体 |
US20090098191A1 (en) * | 2007-10-16 | 2009-04-16 | Anderson Christopher G | Use of bases to stabilize transdermal formulations |
EP2214661A4 (en) * | 2007-10-18 | 2012-10-03 | Medicis Pharmaceutical Corp | AQUEOUS RETINOID AND BENZOYL PEROXIDE GEL |
US20090123551A1 (en) * | 2007-11-13 | 2009-05-14 | Meritage Pharma, Inc. | Gastrointestinal delivery systems |
SI3354276T1 (sl) | 2007-11-13 | 2020-09-30 | Meritage Pharma, Inc. | Sestavki za zdravljenje gastrointestinalnega vnetja |
US20090143343A1 (en) * | 2007-11-13 | 2009-06-04 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
US20100216754A1 (en) * | 2007-11-13 | 2010-08-26 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
NZ586302A (en) | 2007-12-21 | 2013-03-28 | Galderma Lab Inc | Pre-surgical treatment using brimonidine applied topically to reduce bleeding or bruising |
US20090176719A1 (en) * | 2008-01-07 | 2009-07-09 | Liolabs Llc | Compositions and methods for treating perioral dermatitis |
CA2717899A1 (en) * | 2008-03-17 | 2009-09-24 | Glenmark Pharmaceuticals Limited | Stable fixed dose topical formulation |
US20090264392A1 (en) * | 2008-04-21 | 2009-10-22 | Meritage Pharma, Inc. | Treating eosinophilic esophagitis |
CA2724804A1 (en) * | 2008-05-16 | 2009-11-19 | Galderma Research & Development | Therapy regimen for treating acne related diseases |
EP2299810B1 (en) | 2008-06-05 | 2020-01-01 | Bausch Health Ireland Limited | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
EP2293777B1 (en) * | 2008-06-24 | 2015-02-25 | Intervet International B.V. | Pharmaceutical transdermal compositions and method for treating inflammation in cattle |
WO2010047831A1 (en) * | 2008-10-23 | 2010-04-29 | Nycomed Us Inc. | Stable metronidazole gel formulations |
US9775802B2 (en) | 2009-03-24 | 2017-10-03 | Bausch & Lomb Incorporated | Method for preparing suspensions of low-solubility materials |
US20100247666A1 (en) * | 2009-03-24 | 2010-09-30 | Macleod Steven K | Method for Preparing Suspensions of Low-Solubility Materials |
US8618164B2 (en) | 2009-03-31 | 2013-12-31 | Nuvo Research Inc. | Treatment of pain with topical diclofenac compounds |
WO2010144865A2 (en) * | 2009-06-12 | 2010-12-16 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
DK2473161T3 (en) | 2009-08-31 | 2017-09-11 | Dr Reddys Laboratories Ltd | TOPICAL FORMULATIONS INCLUDING A STEROID |
EP2329849B1 (en) | 2009-11-18 | 2015-04-29 | Galderma Research & Development | Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder |
US8394800B2 (en) | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
US8916562B2 (en) | 2010-03-26 | 2014-12-23 | Galderma Research & Development Snc | Methods and compositions for safe and effective treatment of telangiectasia |
WO2011117377A2 (en) | 2010-03-26 | 2011-09-29 | Galderma Research & Development | Improved methods and compositions for safe and effective treatment of erythema |
AU2011273510B2 (en) | 2010-06-30 | 2015-04-16 | Galderma Research & Development | Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor |
CA2810746A1 (en) | 2010-06-30 | 2012-01-05 | Galderma Research & Development | Method for preventing or treating skin tumor |
NO2444068T3 (zh) | 2010-10-21 | 2014-12-20 | ||
US8053427B1 (en) | 2010-10-21 | 2011-11-08 | Galderma R&D SNC | Brimonidine gel composition |
US11957753B2 (en) | 2010-11-22 | 2024-04-16 | Bausch Health Ireland Limited | Pharmaceutical formulations containing corticosteroids for topical administration |
US8809307B2 (en) | 2010-11-22 | 2014-08-19 | Dow Pharmaceutical Sciences, Inc. | Pharmaceutical formulations containing corticosteroids for topical administration |
WO2013016072A1 (en) | 2011-07-22 | 2013-01-31 | Allergan, Inc. | Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases |
WO2013019974A1 (en) | 2011-08-02 | 2013-02-07 | Medicis Pharmaceutical Corporation | Compositions comprising a retinoid and a lincosamide antibiotic for use in treating rosacea |
RU2014119919A (ru) | 2011-10-19 | 2015-11-27 | Галдерма С.А. | Способ лечения капиллярных гемангиом |
RU2014119879A (ru) | 2011-10-19 | 2015-11-27 | Галдерма С.А. | Способ снижения прилива крови к лицу при систематическом использовании ингибиторов фосфодиэстеразы типа 5 |
US9283217B2 (en) | 2011-11-10 | 2016-03-15 | Allergan, Inc. | Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |
UA109359C2 (xx) | 2011-11-10 | 2015-08-10 | Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном | |
RU2548714C2 (ru) * | 2012-05-03 | 2015-04-20 | Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") | Фармацевтическая композиция для лечения угревой болезни и способ ее получения |
US20140112959A1 (en) | 2012-10-18 | 2014-04-24 | MiCal Pharmaceuticals LLC - H Series, a Series of MiCal Pharmaceuticals LLC, a Multi-Division Limite | Topical steroid composition and method |
RU2530644C2 (ru) * | 2012-11-01 | 2014-10-10 | Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") | Противоугревая фармацевтическая композиция и способ ее получения |
EP3919505B1 (en) | 2013-01-16 | 2023-08-30 | Emory University | Uses of cas9-nucleic acid complexes |
CN105658221B (zh) | 2013-09-26 | 2022-05-10 | 高德美国际公司 | 用于治疗萎缩性皮肤瘢痕形成的前列腺素F2α及其类似物 |
US10201481B2 (en) * | 2014-03-07 | 2019-02-12 | The Procter & Gamble Company | Personal care compositions and methods of making same |
US20160184431A1 (en) | 2014-03-11 | 2016-06-30 | Promius Pharma Llc | Topical compositions comprising a corticosteroid |
US9012402B1 (en) * | 2014-06-11 | 2015-04-21 | James Blanchard | Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation |
CN104473865A (zh) * | 2014-11-17 | 2015-04-01 | 重庆华邦制药有限公司 | 地奈德凝胶剂及其制备方法 |
KR20170110083A (ko) | 2014-12-23 | 2017-10-10 | 인털렉츄얼 프라퍼티 어쏘시에이츠, 엘엘씨 | 경피 투여를 위한 방법 및 제형 |
US10117911B2 (en) | 2015-05-29 | 2018-11-06 | Agenovir Corporation | Compositions and methods to treat herpes simplex virus infections |
ES2812451T3 (es) | 2015-06-18 | 2021-03-17 | Bausch Health Ireland Ltd | Composiciones tópicas que comprenden un corticosteroide y un retinoide para tratar la psoriasis |
EP3322401A1 (en) | 2015-07-13 | 2018-05-23 | Dr. Reddy's Laboratories Ltd. | Topical retinoid compositions |
CN106474059A (zh) * | 2015-08-27 | 2017-03-08 | 重庆华邦制药有限公司 | 一种质量更加稳定的地奈德洗剂 |
CN106474047A (zh) * | 2015-08-27 | 2017-03-08 | 重庆华邦制药有限公司 | 一种对光稳定的地奈德制剂 |
CN106474048A (zh) * | 2015-08-27 | 2017-03-08 | 重庆华邦制药有限公司 | 一种质量更加稳定的地奈德凝胶制剂 |
WO2017172761A1 (en) | 2016-03-28 | 2017-10-05 | Allergan, Inc. | Phenyl urea derivatives as n-formyl peptide receptor modulators |
US11812939B2 (en) | 2017-05-15 | 2023-11-14 | Cornell University | Device and system for repairing intervertebral disc herniation and methods of use |
US10779525B2 (en) | 2018-01-16 | 2020-09-22 | Zin Research LLC | Treatment compound and method of application for hoof or foot disease in animals |
US10653656B2 (en) | 2018-04-05 | 2020-05-19 | Bausch Health Ireland Limited | Topical pharmaceutical compositions for treating skin conditions |
US20200138822A1 (en) * | 2018-11-06 | 2020-05-07 | Tim COTE | Topical compositions comprising pentoxifylline and methods of treatment using the same |
FR3090385B1 (fr) * | 2018-12-21 | 2021-01-08 | Pf Medicament | Composition émolliente sous forme d’émulsion |
CN111743853A (zh) * | 2019-03-29 | 2020-10-09 | 天津金耀集团有限公司 | 一种近中性丁酸氢化可的松的外用药物组合物 |
US20220040193A1 (en) | 2020-08-04 | 2022-02-10 | Venthera, Inc. | Formulations of phosphoinositide 3-kinase inhibitors |
US20220202841A1 (en) * | 2020-12-24 | 2022-06-30 | Erine A. Kupetsky | Dermatological formulations for treatment of dermatitis |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3969516A (en) * | 1974-12-19 | 1976-07-13 | Nelson Research & Development Company | Composition and method for treatment of acne |
US4497794A (en) | 1980-12-08 | 1985-02-05 | Dermik Laboratories, Inc. | Erythromycin/benzoyl peroxide composition for the treatment of acne |
US4361584A (en) | 1977-10-07 | 1982-11-30 | A.H.C. Pharmacal, Inc. | Composition and method for the treatment of acne |
US4247547A (en) | 1979-03-19 | 1981-01-27 | Johnson & Johnson | Tretinoin in a gel vehicle for acne treatment |
US4387107A (en) | 1979-07-25 | 1983-06-07 | Dermik Laboratories, Inc. | Stable benzoyl peroxide composition |
US4692329A (en) | 1980-12-08 | 1987-09-08 | William H. Rorer, Inc. | Erythromycin/benzoyl peroxide antiacne compositions |
LU83173A1 (fr) | 1981-02-27 | 1981-06-05 | Oreal | Nouvelles compositions cosmetiques pour le traitement des cheveux et de la peau contenant une poudre resultant de la pulverisation d'au moins une plante et un agent de cohesion |
US4514385A (en) | 1981-10-05 | 1985-04-30 | Alcon Laboratories, Inc. | Anti-acne compositions |
CH643138A5 (de) * | 1983-08-29 | 1984-05-30 | Mepha Ag | Indomethacin enthaltende, gelartige salbe. |
LU85111A1 (fr) | 1983-12-01 | 1985-09-12 | Oreal | Composition anti-acnetique a base de peroxyde de benzoyle et d'au moins un filtre solaire |
US5446028A (en) | 1985-12-12 | 1995-08-29 | Dermik Laboratories, Inc. | Anti-acne method and composition |
FR2604357B1 (fr) | 1986-09-30 | 1988-12-02 | Oreal | Composition pharmaceutique et cosmetique anti-acneique |
AU618517B2 (en) | 1986-12-23 | 1992-01-02 | Eugene J. Van Scott | Additives enhancing topical actions of therapeutic agents |
DE3773383D1 (de) * | 1987-03-20 | 1991-10-31 | Curatek Pharmaceuticals | Neue topische metronidazol-formulierungen. |
MY105521A (en) * | 1989-04-17 | 1994-10-31 | Healthpoint Ltd | Moisturizing vehicle for topical application of vitamin a acid. |
EP0481007B1 (en) | 1989-06-07 | 1997-01-22 | BAZZANO, Gail S | SLOW RELEASE VEHICLES FOR MINIMIZING SKIN IRRITANCY OF TOPICAL COMPOSITIONS containing retinoids |
US5122519A (en) * | 1989-06-27 | 1992-06-16 | American Cyanamid Company | Stable, cosmetically acceptable topical gel formulation and method of treatment for acne |
GB9021320D0 (en) | 1990-10-01 | 1990-11-14 | Diomed Dev Ltd | Compositions for topical application |
US5380528A (en) | 1990-11-30 | 1995-01-10 | Richardson-Vicks Inc. | Silicone containing skin care compositions having improved oil control |
DE69208098T2 (de) * | 1991-10-16 | 1996-08-08 | Richardson Vicks Inc | Wässeriges,kosmetisches gel,mit niedrigem ph,das nichtionogene polyacrylamidderivate enthält |
JP3190441B2 (ja) * | 1992-07-20 | 2001-07-23 | エーザイ株式会社 | 塩酸アゼラスチンを含有する安定な製剤 |
US5549914A (en) * | 1992-12-14 | 1996-08-27 | Sween Corporation | Heat stable wound care gel |
US5690923A (en) | 1993-01-07 | 1997-11-25 | Yamanouchi Europe B.V. | Stable topical retinoid compositions |
US5482710A (en) | 1993-07-30 | 1996-01-09 | Chesebrough-Pond'usa Co., Division Of Conopco, Inc. | Cosmetic composition for treatment of pimples and redness |
US5382432A (en) | 1993-11-15 | 1995-01-17 | Elizabeth Arden Company, Division Of Conopco, Inc. | Cosmetic method for treatment of skin |
US5466446A (en) | 1994-02-16 | 1995-11-14 | Stiefel Laboratories, Inc. | Topical compositions containing bensoyl peroxide and clindamycin and method of use thereof |
US5538732A (en) | 1994-04-12 | 1996-07-23 | Creative Products Resource, Inc. | Medicated applicator sheet for topical drug delivery |
US5451405A (en) | 1994-04-25 | 1995-09-19 | Chesebrough-Pond's Usa Co. | Skin treatment composition |
US5445823A (en) | 1994-10-20 | 1995-08-29 | The Procter & Gamble Company | Dermatological compositions and method of treatment of skin lesions therewith |
US5562917A (en) * | 1994-12-23 | 1996-10-08 | Pentech Pharmaceuticals, Inc. | Transdermal administration of apomorphine |
AT408067B (de) | 1995-03-17 | 2001-08-27 | Gebro Pharma Gmbh | Pharmazeutische zusammensetzung zur topischen applizierung und verfahren zu ihrer herstellung |
EP0738510A3 (fr) | 1995-04-20 | 2005-12-21 | L'oreal | Utilisation d'un inhibiteur d'HMG-coenzyme A-reductase pour lutter contre le vieillissement de la peau et pour traiter l'acné. Composition comprenant au moins un inhibiteur HMG-coenzyme A reductase et au moins un actif possédant des propriétes desquamantes |
US5750122A (en) | 1996-01-16 | 1998-05-12 | The Procter & Gamble Company | Compositions for treating hair or skin |
JP3193617B2 (ja) * | 1996-01-29 | 2001-07-30 | カネボウ株式会社 | 清涼感付与剤および人体用組成物 |
US5891451A (en) | 1996-06-25 | 1999-04-06 | Elizabeth Arden Company, Division Of Conopco, Inc. | Skin treatment with salicylic acid esters |
FR2753626B1 (fr) * | 1996-09-20 | 1998-11-06 | Centre International De Rech Dermatologiques Galderma Cird Galderma | Nouvelles compositions topiques sous forme d'emulsion fluide h/e a forte teneur en glycol pro-penetrant |
JPH1179948A (ja) * | 1997-09-12 | 1999-03-23 | Noevir Co Ltd | 養毛剤及び毛髪用化粧料、並びに皮脂分泌抑制用皮膚外用剤 |
US6083996A (en) * | 1997-11-05 | 2000-07-04 | Nexmed Holdings, Inc. | Topical compositions for NSAI drug delivery |
US6387383B1 (en) * | 2000-08-03 | 2002-05-14 | Dow Pharmaceutical Sciences | Topical low-viscosity gel composition |
-
2000
- 2000-08-03 US US09/632,508 patent/US6387383B1/en not_active Expired - Lifetime
-
2001
- 2001-07-24 BR BR0113247-4A patent/BR0113247A/pt active IP Right Grant
- 2001-07-24 CA CA2417646A patent/CA2417646C/en not_active Expired - Lifetime
- 2001-07-24 PL PL360589A patent/PL213237B1/pl unknown
- 2001-07-24 SI SI200131027T patent/SI2052714T1/sl unknown
- 2001-07-24 PT PT80208200T patent/PT2052714E/pt unknown
- 2001-07-24 ES ES08020820.0T patent/ES2437321T3/es not_active Expired - Lifetime
- 2001-07-24 DK DK01957238T patent/DK1304992T3/da active
- 2001-07-24 WO PCT/US2001/023341 patent/WO2002011683A1/en active Application Filing
- 2001-07-24 DK DK08020820.0T patent/DK2052714T3/da active
- 2001-07-24 RU RU2003105831/15A patent/RU2251410C2/ru active IP Right Revival
- 2001-07-24 CN CN018150659A patent/CN1460013B/zh not_active Expired - Lifetime
- 2001-07-24 EP EP01957238A patent/EP1304992B1/en not_active Expired - Lifetime
- 2001-07-24 PT PT01957238T patent/PT1304992E/pt unknown
- 2001-07-24 DE DE60138549T patent/DE60138549D1/de not_active Expired - Lifetime
- 2001-07-24 KR KR1020087008303A patent/KR20080036246A/ko not_active Application Discontinuation
- 2001-07-24 SI SI200130926T patent/SI1304992T1/sl unknown
- 2001-07-24 AU AU7900201A patent/AU7900201A/xx active Pending
- 2001-07-24 ZA ZA200301037A patent/ZA200301037B/xx unknown
- 2001-07-24 AU AU2001279002A patent/AU2001279002B2/en active Active
- 2001-07-24 AT AT01957238T patent/ATE429922T1/de active
- 2001-07-24 CN CN2008100852167A patent/CN101305982B/zh not_active Expired - Lifetime
- 2001-07-24 EP EP08020820.0A patent/EP2052714B1/en not_active Expired - Lifetime
- 2001-07-24 KR KR1020037001564A patent/KR100840169B1/ko active IP Right Grant
- 2001-07-24 JP JP2002517021A patent/JP4988129B2/ja not_active Expired - Lifetime
- 2001-07-24 ES ES01957238T patent/ES2326955T3/es not_active Expired - Lifetime
- 2001-07-24 MX MXPA03001006A patent/MXPA03001006A/es active IP Right Grant
- 2001-07-31 AR ARP010103660A patent/AR030093A1/es not_active Application Discontinuation
-
2002
- 2002-03-08 US US10/096,516 patent/US6517847B2/en not_active Expired - Lifetime
-
2009
- 2009-05-18 HK HK09104488.2A patent/HK1125847A1/xx not_active IP Right Cessation
- 2009-06-29 CY CY20091100677T patent/CY1109189T1/el unknown
-
2013
- 2013-10-30 BE BE2013C060C patent/BE2013C060I2/nl unknown
- 2013-11-21 CY CY20131101045T patent/CY1114646T1/el unknown
-
2014
- 2014-01-23 CY CY2014005C patent/CY2014005I2/el unknown
- 2014-03-18 LU LU92401C patent/LU92401I2/fr unknown
- 2014-07-04 FR FR14C0053C patent/FR14C0053I1/fr active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101305982B (zh) | 局部凝胶给药体系 | |
AU2001279002A1 (en) | Topical gel delivery system | |
US6238683B1 (en) | Anhydrous topical skin preparations | |
AU666169B2 (en) | Compositions of clindamycin and benzoyl peroxide for acne treatment | |
US8735393B2 (en) | Anhydrous topical skin preparations | |
AU2003228612B2 (en) | Pharmaceutical Composition | |
US8268790B2 (en) | Dermatalogical formulations | |
JP2009500336A (ja) | 局所用皮膚治療組成物 | |
EP2114392A1 (en) | Use of adapalene and benzoyl peroxide for the long term treatment of acne vulgaris | |
RU2548714C2 (ru) | Фармацевтическая композиция для лечения угревой болезни и способ ее получения | |
CA2345501A1 (en) | Anhydrous topical skin preparations | |
MXPA00007720A (en) | Anhydrous topical skin preparations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: DOW PHARMACEUTICAL SCIENCES CO., LTD. Free format text: FORMER OWNER: DOW PHARMACEUTICAL SCIENCES CO.,LTD. Effective date: 20090710 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20090710 Address after: American California Applicant after: Dow Pharmaceutical Sciences Address before: American California Applicant before: Dow Pharmaceutical Sciences |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1125847 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1125847 Country of ref document: HK |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190916 Address after: Ai Er Landubailin Patentee after: Bosch Health Ireland Ltd. Address before: American California Patentee before: Dow Pharmaceutical Sciences |
|
CX01 | Expiry of patent term |
Granted publication date: 20111214 |
|
CX01 | Expiry of patent term |